The Association Between Radioiodine Refractory in Papillary Thyroid Carcinoma, Sodium/Iodide Symporter Expression, and BRAF V600E Mutation

To study the association between radioiodine refractory papillary thyroid carcinoma, sodium/iodide symporter (NIS) expression, and the mutation. A study was conducted on 30 radioiodine refractory papillary thyroid carcinoma patients and 30 radioiodine-avid papillary thyroid carcinoma patients. The e...

Full description

Saved in:
Bibliographic Details
Published in:OncoTargets and therapy 2021, Vol.14, p.3959-3969
Main Authors: Anekpuritanang, Tauangtham, Uataya, Maythad, Claimon, Apichaya, Laokulrath, Natthawadee, Pongsapich, Warut, Pithuksurachai, Paveena
Format: Article
Language:English
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites
container_end_page 3969
container_issue
container_start_page 3959
container_title OncoTargets and therapy
container_volume 14
creator Anekpuritanang, Tauangtham
Uataya, Maythad
Claimon, Apichaya
Laokulrath, Natthawadee
Pongsapich, Warut
Pithuksurachai, Paveena
description To study the association between radioiodine refractory papillary thyroid carcinoma, sodium/iodide symporter (NIS) expression, and the mutation. A study was conducted on 30 radioiodine refractory papillary thyroid carcinoma patients and 30 radioiodine-avid papillary thyroid carcinoma patients. The expressions of sodium/iodide symporter and mutated protein were determined by immunohistochemistry using formalin-fixed, paraffin-embedded tissue. The mutated protein was identified in 26 radioiodine refractory papillary thyroid carcinoma subjects (86.7%) and 22 radioiodine-avid papillary thyroid carcinoma subjects (73.3%), with no significant difference between the 2 groups ( = 0.3). Sodium/iodide symporter expression was detected in 4 of 30 cases (13.3%) from the radioiodine-avid papillary thyroid carcinoma group but was negative for all radioiodine refractory cases. There was no association between sodium/iodide symporter expression and radioiodine refractory papillary thyroid carcinoma ( = 0.11). Cases with positive NIS expression were likely negative for mutation (3/4; = 0.02). Papillary thyroid carcinomas with mutation were more likely to be negative for NIS expression. mutation and NIS expressions cannot be used to predict radioiodine sensitivity.
doi_str_mv 10.2147/OTT.S308910
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_2549689054</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2549689054</sourcerecordid><originalsourceid>FETCH-LOGICAL-p565-285f64b9961de1f5567b5f6e75620a03a4b50964e05f5e6a9583177f0f1d85563</originalsourceid><addsrcrecordid>eNpNkMtOwzAQRS0EoqWwYo-8ZNG0dvxIsmyrFioVFbUR28hJJqpREwc7EfQX-GosHhKrOzM6M1d3ELqlZBJSHk23aTrZMxInlJyhIaVRHMiEkfN_9QBdOfdKiJRxyC_RgPGQcS7FEH2mB8Az50yhVadNg-fQvQM0eKdKbbQpdQN4B5VVRWfsCesGP6tWH4_KN-nhZI0u8ULZQjemVmO89xt9PV17KQHvT3VrbAcWLz9aC855hzFWTYnnu9kKv0hClvip776tr9FFpY4Obn51hNLVMl08Bpvtw3ox2wStkCIIY1FJnieJpCXQSggZ5X4CkZAhUYQpnguSSA5EVAKkSkTMaBRVpKJl7Gk2Qvc_Z1tr3npwXVZrV4BP1IDpXRYKnsg4IYJ79O4X7fMayqy1uva5s7_3sS-AinDS</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2549689054</pqid></control><display><type>article</type><title>The Association Between Radioiodine Refractory in Papillary Thyroid Carcinoma, Sodium/Iodide Symporter Expression, and BRAF V600E Mutation</title><source>Open Access: PubMed Central</source><source>Taylor &amp; Francis Open Access</source><source>Publicly Available Content Database</source><creator>Anekpuritanang, Tauangtham ; Uataya, Maythad ; Claimon, Apichaya ; Laokulrath, Natthawadee ; Pongsapich, Warut ; Pithuksurachai, Paveena</creator><creatorcontrib>Anekpuritanang, Tauangtham ; Uataya, Maythad ; Claimon, Apichaya ; Laokulrath, Natthawadee ; Pongsapich, Warut ; Pithuksurachai, Paveena</creatorcontrib><description>To study the association between radioiodine refractory papillary thyroid carcinoma, sodium/iodide symporter (NIS) expression, and the mutation. A study was conducted on 30 radioiodine refractory papillary thyroid carcinoma patients and 30 radioiodine-avid papillary thyroid carcinoma patients. The expressions of sodium/iodide symporter and mutated protein were determined by immunohistochemistry using formalin-fixed, paraffin-embedded tissue. The mutated protein was identified in 26 radioiodine refractory papillary thyroid carcinoma subjects (86.7%) and 22 radioiodine-avid papillary thyroid carcinoma subjects (73.3%), with no significant difference between the 2 groups ( = 0.3). Sodium/iodide symporter expression was detected in 4 of 30 cases (13.3%) from the radioiodine-avid papillary thyroid carcinoma group but was negative for all radioiodine refractory cases. There was no association between sodium/iodide symporter expression and radioiodine refractory papillary thyroid carcinoma ( = 0.11). Cases with positive NIS expression were likely negative for mutation (3/4; = 0.02). Papillary thyroid carcinomas with mutation were more likely to be negative for NIS expression. mutation and NIS expressions cannot be used to predict radioiodine sensitivity.</description><identifier>ISSN: 1178-6930</identifier><identifier>EISSN: 1178-6930</identifier><identifier>DOI: 10.2147/OTT.S308910</identifier><identifier>PMID: 34234465</identifier><language>eng</language><publisher>New Zealand</publisher><ispartof>OncoTargets and therapy, 2021, Vol.14, p.3959-3969</ispartof><rights>2021 Anekpuritanang et al.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><orcidid>0000-0001-7027-5235 ; 0000-0003-0688-441X ; 0000-0003-1274-6988</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,4024,27923,27924,27925,37013</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34234465$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Anekpuritanang, Tauangtham</creatorcontrib><creatorcontrib>Uataya, Maythad</creatorcontrib><creatorcontrib>Claimon, Apichaya</creatorcontrib><creatorcontrib>Laokulrath, Natthawadee</creatorcontrib><creatorcontrib>Pongsapich, Warut</creatorcontrib><creatorcontrib>Pithuksurachai, Paveena</creatorcontrib><title>The Association Between Radioiodine Refractory in Papillary Thyroid Carcinoma, Sodium/Iodide Symporter Expression, and BRAF V600E Mutation</title><title>OncoTargets and therapy</title><addtitle>Onco Targets Ther</addtitle><description>To study the association between radioiodine refractory papillary thyroid carcinoma, sodium/iodide symporter (NIS) expression, and the mutation. A study was conducted on 30 radioiodine refractory papillary thyroid carcinoma patients and 30 radioiodine-avid papillary thyroid carcinoma patients. The expressions of sodium/iodide symporter and mutated protein were determined by immunohistochemistry using formalin-fixed, paraffin-embedded tissue. The mutated protein was identified in 26 radioiodine refractory papillary thyroid carcinoma subjects (86.7%) and 22 radioiodine-avid papillary thyroid carcinoma subjects (73.3%), with no significant difference between the 2 groups ( = 0.3). Sodium/iodide symporter expression was detected in 4 of 30 cases (13.3%) from the radioiodine-avid papillary thyroid carcinoma group but was negative for all radioiodine refractory cases. There was no association between sodium/iodide symporter expression and radioiodine refractory papillary thyroid carcinoma ( = 0.11). Cases with positive NIS expression were likely negative for mutation (3/4; = 0.02). Papillary thyroid carcinomas with mutation were more likely to be negative for NIS expression. mutation and NIS expressions cannot be used to predict radioiodine sensitivity.</description><issn>1178-6930</issn><issn>1178-6930</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><recordid>eNpNkMtOwzAQRS0EoqWwYo-8ZNG0dvxIsmyrFioVFbUR28hJJqpREwc7EfQX-GosHhKrOzM6M1d3ELqlZBJSHk23aTrZMxInlJyhIaVRHMiEkfN_9QBdOfdKiJRxyC_RgPGQcS7FEH2mB8Az50yhVadNg-fQvQM0eKdKbbQpdQN4B5VVRWfsCesGP6tWH4_KN-nhZI0u8ULZQjemVmO89xt9PV17KQHvT3VrbAcWLz9aC855hzFWTYnnu9kKv0hClvip776tr9FFpY4Obn51hNLVMl08Bpvtw3ox2wStkCIIY1FJnieJpCXQSggZ5X4CkZAhUYQpnguSSA5EVAKkSkTMaBRVpKJl7Gk2Qvc_Z1tr3npwXVZrV4BP1IDpXRYKnsg4IYJ79O4X7fMayqy1uva5s7_3sS-AinDS</recordid><startdate>2021</startdate><enddate>2021</enddate><creator>Anekpuritanang, Tauangtham</creator><creator>Uataya, Maythad</creator><creator>Claimon, Apichaya</creator><creator>Laokulrath, Natthawadee</creator><creator>Pongsapich, Warut</creator><creator>Pithuksurachai, Paveena</creator><scope>NPM</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-7027-5235</orcidid><orcidid>https://orcid.org/0000-0003-0688-441X</orcidid><orcidid>https://orcid.org/0000-0003-1274-6988</orcidid></search><sort><creationdate>2021</creationdate><title>The Association Between Radioiodine Refractory in Papillary Thyroid Carcinoma, Sodium/Iodide Symporter Expression, and BRAF V600E Mutation</title><author>Anekpuritanang, Tauangtham ; Uataya, Maythad ; Claimon, Apichaya ; Laokulrath, Natthawadee ; Pongsapich, Warut ; Pithuksurachai, Paveena</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p565-285f64b9961de1f5567b5f6e75620a03a4b50964e05f5e6a9583177f0f1d85563</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Anekpuritanang, Tauangtham</creatorcontrib><creatorcontrib>Uataya, Maythad</creatorcontrib><creatorcontrib>Claimon, Apichaya</creatorcontrib><creatorcontrib>Laokulrath, Natthawadee</creatorcontrib><creatorcontrib>Pongsapich, Warut</creatorcontrib><creatorcontrib>Pithuksurachai, Paveena</creatorcontrib><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>OncoTargets and therapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Anekpuritanang, Tauangtham</au><au>Uataya, Maythad</au><au>Claimon, Apichaya</au><au>Laokulrath, Natthawadee</au><au>Pongsapich, Warut</au><au>Pithuksurachai, Paveena</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The Association Between Radioiodine Refractory in Papillary Thyroid Carcinoma, Sodium/Iodide Symporter Expression, and BRAF V600E Mutation</atitle><jtitle>OncoTargets and therapy</jtitle><addtitle>Onco Targets Ther</addtitle><date>2021</date><risdate>2021</risdate><volume>14</volume><spage>3959</spage><epage>3969</epage><pages>3959-3969</pages><issn>1178-6930</issn><eissn>1178-6930</eissn><abstract>To study the association between radioiodine refractory papillary thyroid carcinoma, sodium/iodide symporter (NIS) expression, and the mutation. A study was conducted on 30 radioiodine refractory papillary thyroid carcinoma patients and 30 radioiodine-avid papillary thyroid carcinoma patients. The expressions of sodium/iodide symporter and mutated protein were determined by immunohistochemistry using formalin-fixed, paraffin-embedded tissue. The mutated protein was identified in 26 radioiodine refractory papillary thyroid carcinoma subjects (86.7%) and 22 radioiodine-avid papillary thyroid carcinoma subjects (73.3%), with no significant difference between the 2 groups ( = 0.3). Sodium/iodide symporter expression was detected in 4 of 30 cases (13.3%) from the radioiodine-avid papillary thyroid carcinoma group but was negative for all radioiodine refractory cases. There was no association between sodium/iodide symporter expression and radioiodine refractory papillary thyroid carcinoma ( = 0.11). Cases with positive NIS expression were likely negative for mutation (3/4; = 0.02). Papillary thyroid carcinomas with mutation were more likely to be negative for NIS expression. mutation and NIS expressions cannot be used to predict radioiodine sensitivity.</abstract><cop>New Zealand</cop><pmid>34234465</pmid><doi>10.2147/OTT.S308910</doi><tpages>11</tpages><orcidid>https://orcid.org/0000-0001-7027-5235</orcidid><orcidid>https://orcid.org/0000-0003-0688-441X</orcidid><orcidid>https://orcid.org/0000-0003-1274-6988</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 1178-6930
ispartof OncoTargets and therapy, 2021, Vol.14, p.3959-3969
issn 1178-6930
1178-6930
language eng
recordid cdi_proquest_miscellaneous_2549689054
source Open Access: PubMed Central; Taylor & Francis Open Access; Publicly Available Content Database
title The Association Between Radioiodine Refractory in Papillary Thyroid Carcinoma, Sodium/Iodide Symporter Expression, and BRAF V600E Mutation
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T07%3A03%3A27IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20Association%20Between%20Radioiodine%20Refractory%20in%20Papillary%20Thyroid%20Carcinoma,%20Sodium/Iodide%20Symporter%20Expression,%20and%20BRAF%20V600E%20Mutation&rft.jtitle=OncoTargets%20and%20therapy&rft.au=Anekpuritanang,%20Tauangtham&rft.date=2021&rft.volume=14&rft.spage=3959&rft.epage=3969&rft.pages=3959-3969&rft.issn=1178-6930&rft.eissn=1178-6930&rft_id=info:doi/10.2147/OTT.S308910&rft_dat=%3Cproquest_pubme%3E2549689054%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-p565-285f64b9961de1f5567b5f6e75620a03a4b50964e05f5e6a9583177f0f1d85563%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2549689054&rft_id=info:pmid/34234465&rfr_iscdi=true